Pampa: Q1 Earnings Snapshot
The Buenos Aires, Argentina-based company said it had profit of $2.81 per share.
The electricity company posted revenue of $414 million in the period.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PAM at https://www.zacks.com/ap/PAM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Clari Wins Inc. 5000 Award for Fourth Consecutive Year, Leading the Future of Revenue AI
Clari redefines how AI agents work and collaborate with all revenue-critical employees across sales, marketing, customer success, and finance SUNNYVALE, Calif., August 20, 2025--(BUSINESS WIRE)--Clari today announced its inclusion in the annual Inc. 5000 list for the fourth consecutive year. This list is the most prestigious ranking of the fastest-growing private companies in America. The list provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment — its entrepreneurial businesses. Past honorees include companies such as Microsoft, Meta, and Oracle. The Most Comprehensive Revenue AI Dataset Enterprises consistently face complex challenges managing revenue across diverse teams, territories, and business models — introducing inefficiencies that cost enterprises billions annually. Clari's platform solves these challenges at scale by pairing predictive AI and machine learning with comprehensive Revenue Context™ – enabling every sales, marketing, customer success, and finance team to collaborate with AI agents, power predictive workflows, and drive growth across the end-to-end revenue cycle. Andy Byrne, CEO of Clari, said: "With the world's top enterprises running revenue within our platform, we uniquely understand everything that's happening to capture Revenue Context as we watch, listen, and understand what every human did, when, and with what outcome. Clari's customers — including Fortune 500 giants — leverage the most comprehensive Revenue AI dataset in the market, powering end-to-end workflows that turn billions of data signals and human actions into predictable, scalable revenue growth." Category Leaders to Come Together to Form Pivotal AI Company for Running Revenue Clari's recognition comes on the heels of a year of significant momentum. Last week, Clari and Salesloft, two Revenue Orchestration category leaders, entered into a definitive agreement to merge. This category-defining move creates a Revenue AI powerhouse that will redefine how humans and AI agents work together to run revenue. The new company will serve more than 5,000 organizations globally across all industries, managing $10 trillion in annual revenue from enterprise customers like Adobe, IBM, 3M, Zoom, and Shopify. The transaction is expected to close in fall, 2025. Celebrating the Most Successful Companies within the Economy's Most Dynamic Segment — its Entrepreneurial Businesses Mike Hofman, editor-in-chief of Inc, said: "Making the Inc. 5000 is always a remarkable achievement but earning a spot this year speaks volumes about a company's tenacity and clarity of vision. These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm — they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy." For the full list, company profiles, and a searchable database by industry and location, visit: About Clari Clari is the only company that delivers Revenue Context to Run Revenue® – running AI and agents at enterprise scale. The Clari Revenue Orchestration Platform leverages all structured and unstructured data from every human- and machine-generated revenue interaction into a single, time-series data model, the world's largest of its kind — managing over $5 trillion in revenue for global enterprises. More than 1,500 organizations – including Adobe, HPE, Cisco, Okta, Thermo Fisher Scientific, and Zoom – run revenue on Clari to improve win rates, prevent slipped deals, forecast with accuracy, and boost the productivity of all revenue-critical employees. Clari: Run Revenue® with AI + Revenue Context. Learn more: About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit View source version on Contacts Media Contact Ashley Nakanoclari@ (+1) 347-453-0910 Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
IREN Ltd. (IREN) Falls as Investors Book Gains
We recently published . IREN Ltd. (NASDAQ:IREN) is one of Tuesday's worst performers. IREN Ltd. snapped a three-day winning streak on Tuesday, shedding 9.54 percent to close at $18.73 apiece as investors resorted to profit-taking to take advantage of the previous days' surge. Additionally, investors appeared to be in a wait-and-see mode ahead of the release of its earnings performance for the full fiscal period of 2025. Copyright: andreykuzmin / 123RF Stock Photo According to the company, it is scheduled to report its financial and operating highlights after market close on August 28, a Thursday, alongside an investor call to elaborate on the results. Investors will be closely watching out for the company's outlook for fiscal year 2026, having achieved its operating hash rate target of 50 EH/s, which is expected to help bolster revenues from Bitcoin mining moving forward. According to the company, a 50 EH/s hash rate could generate $830 million in annualized hardware profit. Further supporting sentiment, IREN Ltd. (NASDAQ:IREN) recently announced that it was able to generate $83.6 million in revenues from 728 Bitcoins mined in July, or 27.6 percent higher than the $65.5 million in revenues from 620 Bitcoins mined in June. Average Bitcoin prices in July were also 8.66 percent higher at $114,891 versus the $105,730 the month before. While we acknowledge the potential of IREN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins the Executive Committee, bringing over 15 years of deep international expertise in capital markets, financial strategy, and governance to the company. Thomas Gidoin is an experienced biopharma finance executive with a strong track record in strategic financial leadership, both in private and public companies. Prior to joining OSE Immunotherapeutics, he served as Chief Financial Officer at Advesya, a privately held Franco-Swiss clinical-stage biotech company in oncology and autoimmune diseases, after having spent 8 years as CFO of GenSight Biologics, a Euronext-listed French biopharma company developing gene therapies for neurodegenerative retinal diseases, where he led the company's financing strategy from the Series B to the IPO on Euronext Paris and a number of follow-on transactions and structured financings. Previously, Thomas was Vice President of Finance at DBV Technologies, where he led the Corporate Finance team and contributed to public offerings and private placements, including the dual listing of the company on the US NASDAQ. Prior to this, Thomas served as Northern Europe Business Controller at PregLem in London, held several positions at Ipsen, including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at Ernst & Young in Paris. He holds master's degrees in international finance from ESGF Paris and in international management from NEOMA Business School. Thomas succeeds Anne-Laure Autret-Cornet, marking a new phase in the company's financial leadership. Nicolas Poirier, Chief Executive Officer, OSE Immunotherapeutics, commented: 'Thomas joins OSE Immunotherapeutics with deep experience in biotech capital markets financing and strategic financial planning. He has a clear understanding of what it takes to support innovation through disciplined execution and rigorous cash management. His arrival comes at a time when financial leadership is key to advancing our two late-stage assets and continuing to leverage our research platform. His expertise will further reinforce the management team to prepare the next phase of growth with clarity and focus.' Thomas Gidoin, Chief Financial Officer, OSE Immunotherapeutics, said: 'I am thrilled to join OSE Immunotherapeutics at such a pivotal moment in its journey. With two late-stage assets in oncology and inflammation, boosted by a highly innovative research platform, the company is well positioned to create meaningful long-term value through clear multiple short-term inflexion points. I look forward to working closely with the leadership team to help unlock the full potential of OSE's innovative pipeline.' ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on LinkedInContacts Fiona Dé Contact Media France: FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 Contact Media US:RooneyPartners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachments EN_2508_20_CFO_vf EN_2508_20_CFO_vfError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
